CNS Drug Discoveries: Neurodegenerative Disorders Chapter

Table of Contents

NEURODEGENERATION

• EXECUTIVE SUMMARY
• THE FACTS
  • What is neurodegeneration and why are we interested in it?
• PATIENT STATISTICS
  • Incidence, diagnosis rates and treatment; now and in the future
• PATIENT MODEL
  • The addressable AD and PD patient population will grow by 2% per annum
    • Summary of AD patient population forecasts 2005A-2012E
    • Summary of PD patient population forecasts 2005A-2012E
• DRUG GROWTH DRIVERS
• DRUG GROWTH RISKS/DAMPENERS

GLOBAL AD/PD MARKET

• Global CNS Market (US$68.7 billion)
• GLOBAL SALES SPLIT
  • AD and PD Global sales split (2005A)
  • AD Global sales split (2005A)
  • PD Global sales split (2005A)
  • US market
    • AD US drugs sales split (2005A)
    • PD US drugs sales split (2005A)
  • European market
    • AD European drugs sales split (2005A)
    • PD European drugs sales split (2005A)
  • Japan
    • Split between AD and PD in Japan (2005A)
  • The major players
    • Market Share of AD players by sales (Dec 2005A)
    • Market Share of PD players by sales (Dec 2005A)
  • Players and Products in 2012
    • Market Share of AD players by sales (Dec 2012E)
  • Players and Products in 2012
    • Market Share of PD players by sales (Dec 2012E)
• CURRENT AD TREATMENTS
• CURRENT PD TREATMENTS
  • Leading Brands
    • Comparison of leading AD drugs
    • Comparison of leading PD drug classes
  • Patent Exposure of Current Products
    • Patent Exposure of Leading AD Brands
    • Patent Exposure of Leading PD Brands
• ANALYSIS OF LEADING BRANDS
  • AD Agents
  • PD Agents
• Acetylcholine Esterase (AChE) Inhibitors
  • Aricept (Eisai)
  • Exelon (Novartis)
  • Razadyne (Johnson & Johnson/Shire)
• NMDA Antagonist
  • Namenda/Ebixa (Forest/Lundbeck)
• Dopamine Agonists
  • Apokyn (Britannia/Vernalis)
  • Neupro (Schwarz Pharma)
  • Sifrol/Mirapex/Mirapexin (Boehringer Ingelheim)
  • Requip (GlaxoSmithKline)
• Monoaminoxidase (MAO) Inhibitors
  • Azilect (Lundbeck/Teva)
• Catechol-O-Methyltransferase (COMT) Inhibitors
  • Comtan/Comtess & Stalevo (Novartis)
• GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005 - 2012
  • Sales Forecasts of Current Leading AD Drugs
  • Sales Forecasts of Current Leading PD Drugs 2005 - 2012
  • Model assumptions
• NEW DRUGS IN R&D
  • Drugs in Development to Treat AD and PD
• ANALYSIS OF PHASE III DRUGS
  • New Drugs in Phase III Development to Treat AD and PD
  • AD Agents
  • PD Agents
• AD Agents
  • Alzhemed (Neurochem)
  • Flurizan (Myriad Genetics)
  • Phenserine (Axonyx)
  • Xaliproden (sanofi-aventis)
• Parkinson' s Disease
  • E2007 (Eisai)
  • Istradefylline (Kyowa Hakko)
  • Safinamide (Newron)
  • SLV308 (Solvay)
  • Spheramine (Schering AG/Titan)
• GLOBAL SALES FORECASTS OF PHASE III AD and PD DRUGS 2006 - 2012
  • Sales Forecasts of Phase III Developmental AD and PD Drugs
  • Model assumptions
• ANALYSIS OF PHASE II DRUGS
  • New Drugs in Early Clinical Development to Treat AD and PD
  • AD Agents
  • PD Agents
• AD agents
  • Bapineuzumab (Wyeth/Elan)
  • Other promising Phase II drugs
  • CX717 (Cortex Pharmaceuticals)
  • EVT 101 (Evotec)
  • Ketasyn (Accera)
  • MEM 1003 (Memory Pharmaceuticals)
  • PBT2 (Prana)
  • SGS-742 (Saegis Pharmaceuticals)
• PD drugs
  • SR 57667 (sanofi-aventis)
  • Talampanel (IVAX)
  • VR040 (Vectura)
• COMPETITOR RATIO ANALYSIS PRODUCTS/DRUGS
  • CR Analysis of AD Agents Approved by 2012 - Based on Drug Class
  • CR Analysis of PD Agents Approved by 2012 - Based on Drug Class
• COMPETITOR RATIO ANALYSIS - COMPANIES
  • CR Analysis of AD and PD Agents Approved by 2012 - Based on Company
  • WINNERS & LOSERS
    • Summary of Key Companies and Drugs in the AD and PD Market by 2012
• DISCONTINUATION OF DRUGS
  • AD and PD drugs discontinued from clinical development
• NEURODEGENERATIVE APPENDIX 1
  • Phase transition probability
    • Probability of launch
• NEURODEGENERATIVE APPENDIX 2
  • AD Patient Model
    • Summary of AD Patient Population Forecasts
• NEURODEGENERATIVE APPENDIX 3
  • PD Patient Model
    • Summary of PD Patient Population Forecasts
• NEURODEGENERATIVE APPENDIX 4
  • Global AD Drugs Sales 2005-2012
    • Global AD Drug Sales 2005A-2012E
• NEURODEGENERATIVE APPENDIX 5
  • Global PD Drugs Sales 2005-2012
    • Global PD Drug Sales 2005A-2012E
• NEURODEGENERATIVE APPENDIX 6
  • Competitor Ratio Analysis Criteria
    • Key AD & PD Drugs on the Market by 2012
• NEURODEGENERATIVE GLOSSARY
• NEURODEGENERATIVE REFERENCES
• ACRONYMS